EUCTR2004-002122-22-GB进行中（未招募）1 期
A prospective, multi-centre, double blind, randomized, placebo controlled trial to evaluate the safety and efficacy of ICXP007 in a phase III trial with four-layer therapeutic compression, for treatment of non-infected skin leg ulcers, due to venous insufficiency. - TOPICAL II
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 412
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Individuals who have a graft-ready venous leg ulcer of at least 3 months duration, which has not, responded to standard conventional therapy.
- •2. Individuals who have an Ankle Brachial Pressure Index (ABPI/ABI) of greater than or equal to 0.8 measured by Doppler sonography.
- •3. Individuals who have venous incompetency as defined by > 1.0 seconds in vein segments on standing reflux exam by duplex or an abnormal venous refill time of < 21 seconds by PPG or > 2 cc per second by APG. Duplex or PPG/APG will be used to establish venous insuffciency. Doppler will be utilized to rule out arterial disease.
- •4. Individuals who have a target wound which is between 2 cm squared to 20 cm squared in area at the screening assessment.
- •5. Individuals who are ambulatory.
- •6. Individuals who have voluntarily signed and dated a patient Informed Consent Form (ICF).
- •7. Individuals, who are, in the opinion of the investigator, able to understand this study, co-operate with teh study procedures and are willing to return to the clinci for all the required follow-up visits.
- •8. Sub-study only: Patients who are Female
- •9. Sub-study only: Have a coagulation profile which, in the opinion of the Investigator, would not result in excessive bleeding during biopsy procedure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Indiviudals with a known hypersensitivity to Aprotinin or any other constitutents of Tisseel VH S/D, i.e. fibrinogen (human), thrombin (human) and calcium chloride, bovine and porcine products.
- •2. Individuals who have a haemoglobin or serum albumin level which is < 10 g / dL or < 2.5 g / dL respectively, or is otherwise outside the normal range and deemed clinically significant.
- •3. Females who are pregnant, lactating, or who have not reached menopause and are not abstinent or practising an acceptable means of birth control as determined by the Investigator for the duration of the study.
- •4. Individuals younger than 18 years of age.
- •5. Individuals with abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range and / or any other abnormal laboratory finding considered clinically significant.
- •6. Individuals who have exposed bone, tendon or fascia visible around the target wound.
- •7. Individuals with evidence of collagen vascular diseases, such as vasculitis or rheumatiod arthritis, under active treatment.
- •8. Individuals with evidence of cellulitis or osteomyelitis during the previous 4 weeks.
- •9. Individuals who have a target wound which shows signs of clinical infection or the Investigator suspects may be severly infected.
- •10. Individuals who have any clinically significant medical condition that would impair wound healing as determined by the investogator, including uncontrolled diabetes as determined by HbA1C (>12%), or immune disease.
- •11. Individuals who are known to abuse alcohol or drugs currently, or to have psychological disorders that could affect follow-up care or treatment outcomes.
- •12. Individuals who have chronic renal insufficiency requiring haemodialysis.
- •13. Individuals who have received short course corticosteriods within 30 days, or oral or parenteral chronic immunosupressants within 90 days prior to treatment.
- •14. Individuals who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment.
- •15. Individuals who have participated in a clinical study of any investigational product within 2 months prior to treatment.
- •16. Individuals who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this study.
- •17. Individuals previously enrolled/randomized in this clinical trial.
- •18. Sub-study only: Individuals who have a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.
- •19. Individuals who have an abnormal PT, PTT or platelet value defined as 1.5 times that of the upper limit of the normal range and/or any other abnormal laboratory finding considered clinically significant.
- •20. Sub-study only: Individuals who are taking more than 2 tablets of 81 mg Aspirin per day or any dose of Coumadin on a regular basis.
研究者
相似试验
进行中（未招募）
不适用
A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin- Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection (IAI).( T.E.A. Study Three days Ertapenem vs three days Ampicillin- sulbactam) - TEA StudyEUCTR2007-002121-80-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
3 期
To study safety and efficacy of Saroglitazar 4mg in HIV associated LipodystrophyCTRI/2014/08/004885Cadila Healthcare Limited105
进行中（未招募）
1 期
Clinical research study with clazosentan to evaluate its effects on preventing complications due to the narrowing of the blood vessels (vasospasm) in the brain, caused by bleeding onto the surface of the braiAneurysmal Subarachnoid HemorrhageMedDRA version: 21.1Level: PTClassification code 10039330Term: Ruptured cerebral aneurysmSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10042316Term: Subarachnoid haemorrhageSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000241-39-ATIdorsia Pharmaceuticals Ltd400
进行中（未招募）
1 期
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping. - CONSCIOUS 2EUCTR2007-002584-27-FRActelion Pharmaceuticals Ltd.765
进行中（未招募）
1 期
Clinical research study with clazosentan to evaluate its effects on preventing complications due to the narrowing of the blood vessels (vasospasm) in the brain, caused by bleeding onto the surface of the braiEUCTR2018-000241-39-SEIdorsia Pharmaceuticals Ltd400